We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
(-16%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-23.28%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$2.73M |
| 2 |
Pfizer
PFE
|
+$2.42M |
| 3 |
argenx
ARGX
|
+$2.33M |
| 4 |
VYNE Therapeutics
VYNE
|
+$2.08M |
| 5 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$3.38M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$2.95M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$2.75M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$2.58M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.47% |
| 2 | Real Estate | 11.94% |
| 3 | Financials | 4.93% |
| 4 | Consumer Discretionary | 2.41% |
| 5 | Industrials | 2.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rithm Capital
RITM
$5.2B
| $4.28M | 2.87% |
400,966
-106,311
| -21% | -$1.06M |
|
|
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $4.27M | 2.87% |
105,000
| – | – |
|
3
BioCryst Pharmaceuticals
BCRX
$2.36B
| $4.04M | 2.71% |
675,000
+26,000
| +4% | +$151K |
|
4
Pacira BioSciences
PCRX
$1.01B
| $3.96M | 2.66% |
117,500
+14,500
| +14% | +$424K |
|
5
Harmony Biosciences
HRMY
$1.96B
| $3.94M | 2.65% |
122,000
| – | – |
|
6
Embecta
EMBC
$193M
| $3.79M | 2.54% |
200,000
-7,000
| -3% | -$115K |
|
|
IMGN
7
DELISTED
Immunogen Inc
IMGN
| $3.78M | 2.54% |
127,500
+65,000
| +104% | +$1.29M |
|
8
Coherus Oncology
CHRS
$216M
| $3.33M | 2.24% |
1,000,000
+87,500
| +10% | +$234K |
|
|
WBA
9
DELISTED
Walgreens Boots Alliance
WBA
| $3.13M | 2.1% |
120,000
-105,000
| -47% | -$2.35M |
|
|
10
argenx
ARGX
$53.8B
| $2.95M | 1.98% |
7,750
+5,000
| +182% | +$2.33M |
|
|
ABVX
11
Abivax
ABVX
$11.9B
| $2.86M | 1.92% |
+267,500
| New | +$2.73M |
|
12
uniQure
QURE
$2.77B
| $2.85M | 1.91% |
421,025
+29,525
| +8% | +$195K |
|
|
EFC
13
Ellington Financial
EFC
$1.7B
| $2.82M | 1.89% |
221,602
-17,669
| -7% | -$224K |
|
14
Ironwood Pharmaceuticals
IRWD
$635M
| $2.8M | 1.88% |
245,000
-47,500
| -16% | -$470K |
|
15
UroGen Pharma
URGN
$1.96B
| $2.33M | 1.56% |
155,000
-10,000
| -6% | -$130K |
|
|
16
Pfizer
PFE
$143B
| $2.3M | 1.55% |
+80,000
| New | +$2.42M |
|
|
DX
17
Dynex Capital
DX
$2.87B
| $2.27M | 1.53% |
181,492
| – | – |
|
18
Amylyx Pharmaceuticals
AMLX
$1.97B
| $2.22M | 1.49% |
151,000
+5,500
| +4% | +$84.3K |
|
|
19
Invesco NASDAQ 100 ETF
QQQM
$96.3B
| $2.1M | 1.41% |
+12,478
| New | +$1.95M |
|
20
Invesco QQQ Trust
QQQ
$466B
| $2.1M | 1.41% |
+5,122
| New | +$1.94M |
|
|
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
| $1.99M | 1.33% |
140,000
+7,500
| +6% | +$85.2K |
|
|
RVNC
22
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.93M | 1.3% |
220,000
+30,000
| +16% | +$246K |
|
23
DocGo
DCGO
$64.3M
| $1.73M | 1.16% |
310,000
+302,500
| +4,033% | +$1.74M |
|
|
ADAM
24
Adamas Trust
ADAM
$807M
| $1.71M | 1.15% |
200,963
| – | – |
|
25
Medtronic
MDT
$106B
| $1.69M | 1.13% |
20,500
+16,500
| +413% | +$1.26M |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.
- AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
- AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
- AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
- AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
- AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
- AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.
Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.